RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.
Stocks · News reference
Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders' In Journal of Medicinal Chemistry
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Contineum Therapeutics shares are trading lower after the company reported its Q2 financial results. The company announced a workforce reduction.
Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientific Officer Daniel Lorrain
Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate